Healthcare -
Biotechnology - NASDAQ - CA
$ 1.68
0 %
$ 74.6 M
Market Cap
-2.43
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
ESSA Pharma Inc.
| Current Assets | 128 M |
| Cash & Short-Term Investments | 127 M |
| Receivables | 163 K |
| Other Current Assets | 636 K |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 295 K |
| Other Non-Current Assets | 257 K |
| Current Liabilities | 3.3 M |
| Accounts Payable | 2.4 M |
| Short-Term Debt | 124 K |
| Other Current Liabilities | 773 K |
| Non-Current Liabilities | 205 K |
| Long-Term Debt | 205 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
ESSA Pharma Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 21.2 M |
| Operating Income | 0 |
| Other Expenses | 28.5 M |
| Net Income | -28.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ESSA Pharma Inc.
| Net Income | -28.5 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.54 M |
| Change in Working Capital | -419 K |
| Others | -712 K |
| Free Cash Flow | -22.7 M |
Wall Street Analysts Price Targets
ESSA Pharma Inc.
Wall Street analysts predict an average 1-year price target for EPIX of $11.3 , with forecasts ranging from
a
low of
$2 to a high of $17 .
EPIX Lowest Price Target
Wall Street Target
2 USD
19.05%
EPIX Average Price Target
Wall Street Target
11.3 USD
574.60%
EPIX Highest Price Target
Wall Street Target
17 USD
911.90%
4. DIVIDEND
ANALYSIS
EPIX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ESSA Pharma Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
12 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
16.6 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
4 months ago
Nov 01, 2024
|
Sell 3.06 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.532 USD |
|
4 months ago
Nov 01, 2024
|
Sell 3.05 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.5259 USD |
|
4 months ago
Nov 01, 2024
|
Sell 3.06 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.5294 USD |
|
4 months ago
Nov 01, 2024
|
Sell 2.84 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 1879583
|
1.513 USD |
|
5 months ago
Sep 09, 2024
|
Sell 4.16 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
6 USD |
|
5 months ago
Sep 03, 2024
|
Sell 12.6 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 2082
|
6.03 USD |
|
9 months ago
May 06, 2024
|
Sell 4.82 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
6.95 USD |
|
10 months ago
Apr 05, 2024
|
Sell 5.51 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
7.94 USD |
|
11 months ago
Mar 05, 2024
|
Sell 6.23 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
8.98 USD |
|
1 year ago
Feb 06, 2024
|
Sell 749 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 72782
|
10.29 USD |
|
1 year ago
Feb 05, 2024
|
Sell 6.42 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
9.25 USD |
|
1 year ago
Feb 05, 2024
|
Sell 5.02 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 500
|
10.04 USD |
|
1 year ago
Jan 16, 2024
|
Sell 17.2 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 1718
|
10.01 USD |
|
1 year ago
Jan 05, 2024
|
Sell 4.27 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 699
|
6.11 USD |
|
1 year ago
Dec 14, 2023
|
Bought
21.2 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 9223
|
2.3 USD |
|
1 year ago
Nov 21, 2023
|
Bought
133 K USD
|
BERGER FRANKLIN M
Director
|
+ 23259
|
5.73 USD |
|
1 year ago
Nov 03, 2023
|
Bought
98.7 K USD
|
BERGER FRANKLIN M
Director
|
+ 16471
|
5.99 USD |
|
1 year ago
Nov 02, 2023
|
Bought
321 K USD
|
BERGER FRANKLIN M
Director
|
+ 60000
|
5.35 USD |
|
2 years ago
Dec 30, 2022
|
Bought
7.97 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 3067
|
2.6 USD |
|
2 years ago
Dec 22, 2022
|
Bought
51.1 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 21367
|
2.39 USD |
|
2 years ago
Dec 14, 2022
|
Sell 75 K
USD
|
BERGER FRANKLIN M
Director
|
- 25000
|
3 USD |
|
2 years ago
Dec 15, 2022
|
Sell 92.8 K
USD
|
BERGER FRANKLIN M
Director
|
- 32000
|
2.9 USD |
|
2 years ago
Dec 15, 2022
|
Sell 143 K
USD
|
BERGER FRANKLIN M
Director
|
- 50000
|
2.86 USD |
|
2 years ago
Dec 16, 2022
|
Sell 134 K
USD
|
BERGER FRANKLIN M
Director
|
- 50000
|
2.67 USD |
|
2 years ago
Dec 20, 2022
|
Sell 110 K
USD
|
BERGER FRANKLIN M
Director
|
- 43617
|
2.53 USD |
|
2 years ago
Dec 21, 2022
|
Sell 91.3 K
USD
|
BERGER FRANKLIN M
Director
|
- 37889
|
2.41 USD |
|
2 years ago
Dec 21, 2022
|
Sell 83.1 K
USD
|
BERGER FRANKLIN M
Director
|
- 34334
|
2.42 USD |
|
2 years ago
Dec 30, 2022
|
Bought
21.6 K USD
|
Wood David S.
Chief Financial Officer
|
+ 8302
|
2.6 USD |
|
2 years ago
Oct 27, 2022
|
Bought
2.25 M USD
|
BIOTECH GROWTH N V
Director
|
+ 500000
|
4.5022 USD |
|
2 years ago
Oct 26, 2022
|
Bought
5.97 M USD
|
BIOTECH GROWTH N V
Director
|
+ 1500000
|
3.979 USD |
|
2 years ago
Jul 18, 2022
|
Bought
947 K USD
|
BB BIOTECH AG
director:
|
+ 300000
|
3.1558 USD |
|
2 years ago
Jul 18, 2022
|
Bought
947 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 300000
|
3.1558 USD |
|
2 years ago
Jul 15, 2022
|
Bought
757 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 241665
|
3.1316 USD |
|
2 years ago
Jul 14, 2022
|
Bought
969 K USD
|
BB BIOTECH AG
director:
|
+ 347204
|
2.7921 USD |
|
2 years ago
Jul 14, 2022
|
Bought
969 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 347204
|
2.7921 USD |
|
2 years ago
Jun 30, 2022
|
Bought
14.5 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 4887
|
2.958 USD |
|
2 years ago
Apr 27, 2022
|
Sell 147 K
USD
|
BB BIOTECH AG
director:
|
- 25100
|
5.8536 USD |
|
2 years ago
Apr 27, 2022
|
Sell 147 K
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 25100
|
5.8536 USD |
|
3 years ago
Aug 18, 2021
|
Bought
2.22 M USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 250000
|
8.8752 USD |
|
4 years ago
Feb 22, 2021
|
Bought
1.54 M USD
|
BERGER FRANKLIN M
Director
|
+ 57000
|
27 USD |
|
21 years ago
Dec 03, 2003
|
Sell 94.3 K
USD
|
CROOKE STANLEY T
Director
|
- 5000
|
18.865 USD |
|
21 years ago
Dec 02, 2003
|
Sell 175 K
USD
|
CROOKE STANLEY T
Director
|
- 9500
|
18.4279 USD |
|
21 years ago
Dec 01, 2003
|
Sell 81.4 K
USD
|
CROOKE STANLEY T
Director
|
- 4500
|
18.0856 USD |
|
21 years ago
Nov 26, 2003
|
Sell 93.9 K
USD
|
CROOKE STANLEY T
Director
|
- 5300
|
17.7189 USD |
|
21 years ago
Nov 25, 2003
|
Sell 148 K
USD
|
CROOKE STANLEY T
Director
|
- 8401
|
17.6536 USD |
|
21 years ago
Nov 24, 2003
|
Sell 14.4 K
USD
|
CROOKE STANLEY T
Director
|
- 823
|
17.5414 USD |
|
21 years ago
Nov 21, 2003
|
Sell 180 K
USD
|
CROOKE STANLEY T
Director
|
- 10104
|
17.8367 USD |
7. News
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against ESSA Pharma Inc.
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
accessnewswire.com
- 1 week ago
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=131270&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
accessnewswire.com
- 1 week ago
ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of ESSA Pharma Inc. investors who were adversely affected by alleged securities fraud between December 12, 2023 and October 31, 2024.
prnewswire.com
- 1 week ago
Levi & Korsinsky Notifies Shareholders of ESSA Pharma Inc.(EPIX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=131093&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 week ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline.
globenewswire.com
- 1 week ago
Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors – Contact The Gross Law Firm
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).
globenewswire.com
- 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIX
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=130980&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 week ago
ESSA Pharma Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 25, 2025.
accessnewswire.com
- 1 week ago
Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=130939&wire=1 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 week ago
Faruqi & Faruqi Reminds ESSA Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 20, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
prnewswire.com
- 1 week ago
EPIX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period").
accessnewswire.com
- 1 week ago
8. Profile
Summary
ESSA Pharma Inc. EPIX
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 74.6 M
Dividend Yield
0.00%
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Contact
999 West Broadway, Vancouver, BC, V5Z 1K5
https://www.essapharma.com
IPO
Date
March 13, 2015
Employees
35
Officers
Dr. Alessandra Cesano M.D., Ph.D.
Chief Medical Officer & Executive Vice President
Dr. David Ross Parkinson M.D.
President, Chief Executive Officer & Director
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA
Chief Financial Officer
Mr. Peter A. Virsik M.B.A., M.S.
Executive Vice President & Chief Operating Officer
Chandtip Chandhasin
Executive
Erica Osbourne
Executive
Erin Rudsinski
Executive
Loleta Harris
Executive
Neil Thapar
Executive
Nkengyal Barber
Executive